Skip to main content
. 2022 Jan 15;3(1):121–128. doi: 10.1002/jha2.359

TABLE 2.

Treatment response on 163 evaluable patients

Overall, N = 163 (%) DRd, N = 126 (%) DVd, N = 37 (%)
Overall response rate 137 (84) 110 (87) 27 (72)
sCR 3 (2) 3 (2) 0
CR 15 (9) 13 (10) 2 (5)
VGPR 34 (21) 27 (21) 7 (19)
PR 85 (52) 67 (53) 18 (49)
VGPR or better 52 (38) 43 (34) 9 (24)
minimal response (MR) 10 (6) 7 (5) 3 (8)
stable disease (SD) 6 (4) 3 (2) 3 (8)
Progressive disease 10 (6) 6 (5) 4 (11)
Median time to response, months (range) 3 (1–12) 3 (1–12) 3 (1–12)